ProfileGDS5678 / 1453335_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 50% 51% 50% 50% 51% 56% 51% 50% 51% 50% 50% 51% 50% 50% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.2448950
GSM967853U87-EV human glioblastoma xenograft - Control 23.2117951
GSM967854U87-EV human glioblastoma xenograft - Control 33.2092650
GSM967855U87-EV human glioblastoma xenograft - Control 43.1319650
GSM967856U87-EV human glioblastoma xenograft - Control 53.1857251
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.5212256
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.3041751
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.1988650
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.1992351
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.1882150
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.2002450
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.1932451
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.2076950
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.2040950